Abstract 366P
Background
Microbiome has been proposed as a promising prognostic biomarker in various types of cancer. Although recent microbiome studies have linked the bacterial microbiome in the oral cavity and nasopharynx to the prognosis of nasopharyngeal carcinoma (NPC), the clinical significance of oral mycobiome, another key player of the oral microbiome, in NPC survival remain unknown.
Methods
We enrolled 476 untreated incident NPC patients from Wuzhou, southern China during March 2010 and December 2013, with follow-up through December 2018. We collected saliva samples at the time of diagnosis and characterized the oral mycobiome using fungal internal transcribed spacer (ITS)-2 sequencing. We analyzed the relationship between oral mycobiome and the overall survival using Cox regression adjusting for multiple confounders.
Results
Overall, the average follow-up of the NPC patients [mean (SD) age, 48.5 (10.7) years; 72% male) was 5.26 years. Patients with lower oral fungal alpha diversity (measured by observed features) had an inferior 5-year overall survival rate (lower group vs. higher group = 54.9% vs. 69.6%, P for log-rank test = 0.007). We found that lower alpha diversity was associated with an increased mortality [lower vs. higher: observed features (fully adjusted hazard ratio [HR] = 1.56, 95% confidence interval [CI] = 1.08-2.25); Simpson diversity (1.50, 1.04-2.15); Shannon diversity (1.79, 1.25-2.56)]. The associations were attenuated when further adjusted for cancer stage at diagnosis, and the significant associations were found only among localized-tumor-stage patients.
Conclusions
Oral mycobiome is a potential prognostic biomarker for patients with NPC and might provide potential guidance for treatment decision.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
The original field work was supported by a grant from the National Cancer Institute at the US National Institutes of Health (grant number: R01 CA115873). This work was supported by the Swedish Research Council (grant numbers: 2015-02625, 2015-06268, 2017-05814, 2019-01429), and the High-level Talents Research Start-up Project of Fujian Medical University (grant numbers: XRCZX2017035 and XRCZX2020034), the National Natural Science Foundation of China (grant number: U22A20322). Yufeng Chen was also partly supported by a scholarship from China Scholarship Council (grant number: 201600160071).
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
203P - Neoadjuvant durvalumab plus chemotherapy for resectable locally advanced esophageal squamous cell carcinoma (ESCC)
Presenter: Jia He
Session: Poster Display
Resources:
Abstract
204P - A radiomics strategy based on CT intra-tumoral and peritumoral regions for preoperative prediction of neoadjuvant chemoradiotherapy for esophageal cancer
Presenter: zhiyang li
Session: Poster Display
Resources:
Abstract
205TiP - IMPACT: Randomized, multicenter, phase III study evaluating the efficacy of immunotherapy (atezolizumab) plus anti-VEGF therapy (bevacizumab) in combination with transcatheter arterial chemoembolization for unresectable hepatocellular carcinoma (HCC)
Presenter: Tatsuya Yamashita
Session: Poster Display
Resources:
Abstract
206TiP - SIERRA: A phase IIIb, single-arm, multicentre study of tremelimumab plus durvalumab for first-line treatment of advanced unresectable hepatocellular carcinoma
Presenter: Stephen Chan
Session: Poster Display
Resources:
Abstract
207TiP - A two-arm randomized open-label prospective design superiority phase III clinical trial to compare the efficacy of docetaxel-oxaliplatin-capecitabine/ 5 -fluorouracil (DOC/F) followed by docetaxel versus CAPOX/mFOLFOX-7 in advanced gastric cancers
Presenter: Prabhat Bhargava
Session: Poster Display
Resources:
Abstract
212P - Mutational landscape and characteristics of ERBB2 in urothelial carcinoma
Presenter: Mingwei Li
Session: Poster Display
Resources:
Abstract
213P - Prognostic significance of absolute lymphocyte count in patients with metastatic renal cell carcinoma treated with first-line combination immunotherapies: Results from the International metastatic renal cell carcinoma database consortium (IMDC)
Presenter: Kosuke Takemura
Session: Poster Display
Resources:
Abstract
214P - Development and prospective validation of a multiplex RNA urine test for noninvasive detection and surveillance of urothelial carcinoma
Presenter: Hua Xu
Session: Poster Display
Resources:
Abstract
215P - Real-world outcomes of first-line tislelizumab plus axitinib in patients with metastatic non-clear cell renal cell carcinoma (mnccRCC)
Presenter: Pei Dong
Session: Poster Display
Resources:
Abstract
216P - Preliminary efficacy and safety results from ‘ReBirth’: A phase II study of risk-based bladder-sparing therapy for MIBC
Presenter: Yijun Shen
Session: Poster Display
Resources:
Abstract